All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-12-12T14:39:15.000Z

AUGMENT: Is the combination of lenalidomide & rituximab efficacious in elderly patients with iNHL?

By Joanna Nikitorowicz-Buniak, Elina Simanovits
Featured
Marek Trněný
Dec 12, 2019
Share:

Bookmark this article

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Marek Trněný, Charles University Hospital, Prague, CZ. We asked: AUGMENT trial: Is the combination of lenalidomide and rituximab efficacious in elderly patients with indolent non-Hodgkin lymphoma?

Marek Trněný gives an overview of the AUGMENT study design and results of the post-hoc analysis of the data in the elderly population. He concludes that the combination is safe and offers clinical benefit to older patients, especially those with follicular lymphoma.

AUGMENT: Is the combination of lenalidomide & rituximab efficacious in elderly patients with iNHL?

More about...
ASH 2019AUGMENTIndolent B-cell lymphomasLenalidomideRituximabTreatment of older patients with lymphoma and CLL

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Phase II study assesses the use of rituximab and bendamustine in frail, elderly DLBCL patients

The authors concluded that they found the combination of bendamustine and rituximab to be a good treatment option showing “promising activity” for elderly...

May 29, 2018
Add bookmark

Phase II study assesses the use of rituximab and bendamustine in frail, elderly DLBCL patients

The authors concluded that they found the combination of bendamustine and rituximab to be a good...

May 29, 2018
Add bookmark

Results from a phase II study: brentuximab plus DTIC is a good choice in elderly, front-line HL patients

The results of this study ought to serve as a template and give rise to additional studies of novel induction regimens for elderly HL patients.

Jan 15, 2018
Add bookmark

Results from a phase II study: brentuximab plus DTIC is a good choice in elderly, front-line HL patients

The results of this study ought to serve as a template and give rise to additional studies of...

Jan 15, 2018

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox